Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3He-MRI and Proton MRI in COPD
NCT02207452Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of salbutamol and ipratropium bromide in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Primary endpoint: Changes in Oxygen Saturation. Started Aug 2010; status: completed.
02
Drugs
salbutamolipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02207452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207452.